CN1735423A - 胃轻瘫的治疗 - Google Patents

胃轻瘫的治疗 Download PDF

Info

Publication number
CN1735423A
CN1735423A CNA038080079A CN03808007A CN1735423A CN 1735423 A CN1735423 A CN 1735423A CN A038080079 A CNA038080079 A CN A038080079A CN 03808007 A CN03808007 A CN 03808007A CN 1735423 A CN1735423 A CN 1735423A
Authority
CN
China
Prior art keywords
glp
val
glu
gastroparesis
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038080079A
Other languages
English (en)
Chinese (zh)
Inventor
J·A·亚库夫斯基
T·D·麦金尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1735423A publication Critical patent/CN1735423A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CNA038080079A 2002-04-10 2003-03-27 胃轻瘫的治疗 Pending CN1735423A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
US60/371,650 2002-04-10

Publications (1)

Publication Number Publication Date
CN1735423A true CN1735423A (zh) 2006-02-15

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038080079A Pending CN1735423A (zh) 2002-04-10 2003-03-27 胃轻瘫的治疗

Country Status (18)

Country Link
US (1) US20050164925A1 (https=)
EP (1) EP1496924A4 (https=)
JP (1) JP2005530732A (https=)
KR (1) KR20040098063A (https=)
CN (1) CN1735423A (https=)
AU (1) AU2003220403A1 (https=)
BR (1) BR0308904A (https=)
CA (1) CA2480858A1 (https=)
EA (1) EA200401345A1 (https=)
EC (1) ECSP045345A (https=)
HR (1) HRP20040939A2 (https=)
IL (1) IL164266A0 (https=)
MX (1) MXPA04009929A (https=)
NO (1) NO20044815L (https=)
NZ (1) NZ535684A (https=)
PL (1) PL373658A1 (https=)
WO (1) WO2003087139A2 (https=)
ZA (1) ZA200408111B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
KR101241862B1 (ko) * 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
JP2007537981A (ja) * 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
EP1793891B1 (en) 2004-08-18 2011-11-09 Metacure Limited Monitoring, analysis, and regulation of eating habits
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
WO2006087712A2 (en) 2005-02-17 2006-08-24 Metacure N.V. Charger with data transfer capabilities
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
JP5755398B2 (ja) 2005-03-18 2015-07-29 ノヴォ ノルディスク アー／エス 伸長されたｇｌｐ−１化合物
US8265758B2 (en) * 2005-03-24 2012-09-11 Metacure Limited Wireless leads for gastrointestinal tract applications
WO2007080595A2 (en) 2006-01-12 2007-07-19 Metacure N.V. Electrode assemblies, tools, and methods for gastric wall implantation
WO2006129321A2 (en) 2005-06-02 2006-12-07 Metacure N.V. Gi lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
ES2495741T3 (es) * 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
US8417329B2 (en) * 2007-05-09 2013-04-09 Metacure Ltd. Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
EP2482840A4 (en) * 2009-08-07 2013-06-26 Mannkind Corp VAL (8) GLP-1 COMPOSITION AND METHOD FOR THE TREATMENT OF REAGENTS AND / OR IRRITATION SYNDROME
CN118767117A (zh) 2010-01-22 2024-10-15 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
WO2011136361A1 (ja) 2010-04-30 2011-11-03 株式会社 三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
EA200401345A1 (ru) 2005-08-25
WO2003087139A2 (en) 2003-10-23
EP1496924A2 (en) 2005-01-19
JP2005530732A (ja) 2005-10-13
NZ535684A (en) 2006-03-31
AU2003220403A1 (en) 2003-10-27
KR20040098063A (ko) 2004-11-18
BR0308904A (pt) 2005-05-03
MXPA04009929A (es) 2006-03-10
WO2003087139A3 (en) 2004-01-08
NO20044815L (no) 2005-01-07
US20050164925A1 (en) 2005-07-28
ECSP045345A (es) 2006-04-19
PL373658A1 (en) 2005-09-05
CA2480858A1 (en) 2003-10-23
EP1496924A4 (en) 2007-05-30
IL164266A0 (en) 2005-12-18
HRP20040939A2 (en) 2004-12-31
ZA200408111B (en) 2005-10-07

Similar Documents

Publication Publication Date Title
CN1735423A (zh) 胃轻瘫的治疗
US9522175B2 (en) Method of enhancing diabetes resolution
CN1501809B (zh) 应用胰高血糖素样促胰岛肽的长期治疗方案
TWI685506B (zh) 包含ＧＬＰ及免疫球蛋白雜合Ｆｃ之融合多肽及其用途
CN103491975B (zh) 酰化胰高血糖素类似物与胰岛素类似物的组合
JP5645339B2 (ja) 摂食行動の修正
ES2330671T3 (es) Amilina y agonistas de amilina para el tratamiento de enfermedades y trastornos psiquiatricos.
ES2319936T3 (es) Metodos para regular la motilidad gastrointestinal.
US20080213288A1 (en) Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
CN106715466A (zh) 作为选择性胰高血糖素受体激动剂的毒蜥外泌肽‑4衍生物
RS67258B1 (sr) Upotreba dugodelujućih glp-1 peptida
AU2002239384A1 (en) Chronic treatment regimen using glucagon-like insulinotropic peptides
JP2014159431A (ja) 血糖降下剤の投与方法
CN105722854A (zh) 用于治疗疾病和病症的降钙素模拟物
EP1888103B1 (en) Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
CN103328006A (zh) 包含胰岛素、烟酰胺和氨基酸的制剂
Gasbjerg et al. Proglucagon-derived peptides: human physiology and therapeutic potential
CN101095942A (zh) 一种包含稳定剂的Exendin注射剂药物配方
EP2010208A1 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
Kaur et al. Hormones and hormones antagonists
KR20060127977A (ko) 지방이상증 치료용 조성물 및 치료 방법
KR20260005268A (ko) 당뇨병 치료
HK1096314A (en) Methods and compositions for the treatment of lipodystrophy
MXPA06007761A (en) Methods and compositions for the treatment of lipodystrophy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication